Indication: Acute Myeloid Leukemia (AML)
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage
Patients in Second or Third Salvage
Line of Therapy: 2nd or 3rd
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Delta-Fly Pharma, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org